Jiangsu Bioperfectus Technologies Co., Ltd.

March 24 of each year is World Tuberculosis (TB) Day. The theme of World TB Day 2023 is Yes! We can end TB!. The date marked the day in 1882 when Dr. Robert Koch announced that he had discovered the bacterium that causes TB, which opened the way towards diagnosing and curing this disease. What to know about TB? Tuberculosis (TB) is a communicable disease that is a major cause of ill health and one of the leading causes of death worldwide. Worldwide, TB is the 13th leading cause of death and the second leading infectious killer after COVID-19 (above HIV/AIDS). TB is caused by the bacillus Mycobacterium tuberculosis, which is spread when people who are sick with TB expel bacteria into the air (e.g. by coughing). About a quarter of the global population is estimated to have been infected with TB. The vast majority have no signs or symptoms of TB disease and are not infectious, although they are at risk of developing active TB disease and becoming infectious. Several studies have shown that in recent decades, on average, 510% of those infected will develop active TB disease over the course of their lives, usually within the first 5 years after initial infection. The disease typically affects the lungs (pulmonary TB) but can affect other sites as well. About WHOs End TB Strategy In 2014 and 2015, all Member States of WHO and the United Nations (UN) committed to ending the TB epidemic, through their adoption of WHOs End TB Strategy and the UN Sustainable Development Goals (SDGs). The strategy included milestones in 2025, for large reductions in the TB incidence rate, the absolute number of TB deaths and costs faced by TB patients and their households. However, the COVID-19 pandemic continues to have a damaging impact on access to TB diagnosis and treatment and the burden of TB disease, progress made in the years up to 2019 has slowed, stalled or reversed, and global TB targets are off track. Intensified efforts backed by every one of us are urgently required to mitigate and reverse the negative impacts of the COVID-19 pandemic on TB. Fig.1. WHOs End TB Strategy:2025 milestones TB Global burden In 2021, an estimated 10.6 million people fell ill with TB worldwide. Six million men, 3.4 million women and 1.2 million children. A total of 1.6 million people died from TB in 2021. Geographically, in 2021, most people who developed TB were in the WHO regions of South-East Asia (45%), Africa (23%) and the Western Pacific (18%), with smaller proportions in the Eastern Mediterranean (8.1%), the Americas (2.9%) and Europe (2.2%). The 30 high TB-burden countries accounted for 87% of all estimated incident cases worldwide. Eight of these countries (Fig. 2) accounted for more than two-thirds of the global total: India (28%), Indonesia (9.2%), China (7.4%), the Philippines (7.0%), Pakistan (5.8%), Nigeria (4.4%), Bangladesh (3.6%) and the Democratic Republic of the Congo (2.9%). Fig.2. Estimated TB incidence in 2021, for countries with at least 100 000 incident cases Note: The countries that rank first to eighth in terms of the number of cases, and that accounted for about two-thirds of global cases in 2021, are labeled. TB can affect anyone, regardless of age or sex (Fig. 3). The highest burden is in adult men, who accounted for 56.5% of all TB cases in 2021; by comparison, adult women accounted for 32.5% and children for 11% of cases. Fig.3. Global estimates of TB incidence (black outline) and case notifications of people newly diagnosed with TB disaggregated by age and sex (female in purple; male in green), 2021 What BioPerfectus can provide to end TB? TB is present in all countries and age groups but it is curable and preventable. Early diagnosis and treatment are essential for the effective control of the TB epidemic. Since 2000, an estimated 74 million lives have been saved through TB diagnosis and treatment. Today, we are proud to launch the Mycobacterium Tuberculosis Real Time PCR Kit. The kit is intended for the in-vitro qualitative detection of Mycobacterium tuberculosis (TB) in human sputum samples, contributing to the confirmatory diagnosis of TB and preventing the further spread of the disease. Dedicated to providing laboratories with comprehensive tests of respiratory infections, BioPerfectus provides the Total PCR Solution with instruments and kits.Pioneering the field of molecular diagnostics, BioPerfectus consistently pursues excellence, embraces innovation, and remains dedicated to addressing health challenges faced by humanity in pursuit of a healthier future. References [1]Global tuberculosis report 2021. Geneva: World Health Organization; 2021 (https://www.who.int/publications/i/item/9789240037021). [2]Global tuberculosis report 2022. Geneva: World Health Organization; 2022 (https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022). [3]Global tuberculosis report 2021. Geneva: World Health Organization; 2021 (https://www.who.int/publications/i/item/9789240037021). [4]Methods used by WHO to estimate the global burden of TB disease. Geneva: World Health Organization; 2021 (https://www.who.int/publications/m/item/methods-used-by-who-to-estimate-the-global-burden-of-tb-disease). [5] https://www.who.int/news-room/fact-sheets/detail/tuberculosis

Vector-Borne Diseases are human illnesses caused by parasites, viruses and bacteria that are transmitted by vectors. Every year there are more than 700,000 deaths from Vector-Borne Diseases. The burden of these diseases is highest in tropical and subtropical areas, and they disproportionately affect the poorest populations. SHANGHAI, CHINA, March 21, 2023Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as BioPerfectus) is pleased to launch the following 6 new Real Time PCR Kits independently developed by BioPerfectus. BioPerfectus provides Vector-Borne Diseases Total Diagnostic Solutions from sample pre-processing to PCR amplification analysis for our partners to rapid response to a global health emergency. Vector-Borne Disease is a kind of infectious disease with arthropods as the transmission vector, which is transmitted to animals and human hosts through bites, mainly including mosquito-borne, tick-borne, mite-borne, lice-borne and flea-borne infectious diseases. Almost everyone has been bitten by bite.Examples of vector-borne diseases include Dengue fever,West Nile Virus, Lyme disease, and malaria. Some Vector-Borne Diseases, like Malaria, have been around for thousands of years. Others, like Tick-Borne Diseases, have been outbroken recently. Past outbreaks also indicate that preparedness is the key to infectious diseases. The capacity to recover, prepare for, and respond to outbreaks is very important. In this way, an earlier window for diagnosis is of great importance. Pioneering the field of molecular diagnostics, BioPerfectus consistently pursues excellence, embraces innovation, and remains dedicated to addressing health challenges faced by humanity in pursuit of a healthier future. Reference [1] https://www.who.int/news-room/fact-sheets/detail/vector-borne-diseases [2] https://www.cdc.gov/ncezid/dvbd/index.html [3] http://publichealth.lacounty.gov/acd/vector.htm

BioPerfectus is committed to supporting the development of public health and has established strong cooperative relationships with governmental health departments and NGOs worldwide to respond jointly to global or regional public health emergencies. Whenever an epidemic outbreak occurs, BioPerfectus provides robust support to our partners to deal with local emergencies. We are pleased to share our efforts in public health in Ecuador, where we have worked closely with the laboratories of the Ecuadorian Ministry of Health to combat the monkeypox outbreak and the COVID-19 pandemic, flu, and other infectious diseasesworldwideby providing BioPerfectus diagnostic solutions. Our Nucleic Acid Extraction System, Real-Time PCR System, and Multiple Assays have played a crucial role in the prompt and accurate detection and diagnosis of infectious diseases.The professionals from the Ministry of Health's laboratories highly value our diagnostic products and technical support. In particular, the high-throughput and automation capabilities of the SMPE-960, developed by BioPerfectus, can extract nucleic acids from 1-96 samples in three independently operating modules simultaneously. This has significantly reduced the turnaround time for test results, allowing for prompt and effective public health interventions. In Ecuador, vector-borne infections, including Dengue, Chikungunya, Yellow Fever, and Zika, are common, and BioPerfectus is always ready to respond to these infectious diseases with timely and accurate detection. We offer a complete set of diagnostic solutions for vector-borne virus detection based on both the Immuno-chromatographic platform and the Multiplex real-time PCR platform, satisfying the detection demands of different infectious procedures. Most vector-borne infections currently have no known treatment or vaccine. Therefore, early diagnosis and monitoring are critical for controlling these infectious diseases and improving treatment outcomes.